Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Altria Group, Inc. filings on SEC EDGAR ↗
The filing details ongoing litigation matters for Altria Group, Inc., including product liability, health care cost recovery, and antitrust cases. Notable pending actions include international health care cost recovery suits in Canada and various class actions related to e-vapor products and 'Lights' cigarette branding.
Altria reported Q3 2026 financial results with net revenues of $6.13 billion and adjusted diluted EPS growth of 4.8%. The company also announced a $1 billion expansion of its share repurchase program and raised its full-year 2026 adjusted EPS guidance.
“Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future.”
Sal Mancuso, Altria’s Chief Executive Officer
“Our strong performance through the first nine months and confidence in our full-year plan allowed us to raise our earnings guidance for the year. We now expect to deliver adjusted diluted EPS in a range of $5.66 to $5.74, representing a growth rate of 4.5% to 6.0% from a base of $5.42 in 2025.”
Altria Group $3B Debt Financing with JPMorgan Chase Bank, N.A. and Citibank, N.A.
Altria Group, Inc. entered into an extension agreement for its $3.0 billion senior unsecured revolving credit facility. The agreement extends the maturity date of the facility by one year, from October 24, 2029, to October 24, 2030.